Is the business good?
How good a business is PBH?
Prestige Consumer Healthcare Inc. earns 8.7% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
8.7%
Return on invested capital · cost of capital 9.0% · 0.32 points below what the capital costs: growth destroys value
- Operating margin
- 28%
Operating margin · Drug Manufacturers - Specialty & Generic median 12% · 12 months to Q4 2026
- Cash conversion
- 1.29×
Cash conversion · 1.13× a year ago · every dollar of reported profit arrived as cash, and more
- Gross margin
- 55%
Gross margin
| Year | Operating margin |
|---|---|
| FY2021 | 32% |
| FY2022 | 30% |
| FY2023 | −2.0% |
| FY2024 | 30% |
| FY2025 | 30% |
| FY2026 | 28% |
Details›
- Gross margin12 months to Q4 2026
- 55%
- Operating margin12 months to Q4 2026
- 28%
- Net margin12 months to Q4 2026
- 17%
- Free cash flow margin
- 23%
- Revenue, trailing twelve months
- $1.09B
- Free cash flow, trailing twelve months
- $246M
- Net income, trailing twelve months
- $190M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 8.7%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.
Drug Manufacturers - Specialty & Generic
Ranks #9 of 28 by Smart Score